Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Feature | Coronavirus (COVID-19)

WHO Database Shows Serious Health Impact of Hydroxychloroquine and Azithromycin Being Used to Treat COVID-19

May 27, 2020 — Two of the front-line drugs being used to treat COVID-19 (SARS-CoV-2) patients are hydroxychloroquine and ...

May 27, 2020

Videos | Coronavirus (COVID-19)

VIDEO: Overview of Hydroxychloroquine and FDA Warning in its use to Treat COVID-19

Marianne Pop, Pharm.D., BCPS, a clinical pharmacist and clinical assistant professor with the regional pharmacy program ...

May 18, 2020

Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals

Icosapent Ethyl Significantly Reduces Revascularizations in Statin Patients

May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy ...

May 17, 2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

News | Stents

TWILIGHT Trial Substudy Examines Bioabsorbable Polymer vs. Durable Polymer Drug-Eluting Stents in High-Risk PCI

May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP) ...

May 17, 2020

News | EP Lab

Etripamil Nasal Spray Does Not Meet Primary Endpoint in Treating Supraventricular Tachycardia

May 13, 2020 — The patient-administered nasal spray drug etripamil did not meet its primary endpoint in treating ...

May 13, 2020

News | Atrial Fibrillation

High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients

May 8, 2020 – A new clinical study found that patients with atrial fibrillation (AF) experienced a high incidence of ...

May 08, 2020

There have been several safety reports to the FDA that COVID-19 patients receiving hydroxychloroquine and chloroquine, either aloneaths and Injuries From Use of Antimalarial Drugs in COVID-19 Patients. he U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors there are serious side effects when using hydroxychloroquine and chloroquine in the off-lable use to treat COVID-19 patients. This includes potentially life-threatening heart rhythms. #COVID19 #SARScov2

Feature | Coronavirus (COVID-19) | Dave Fornell, Editor

FDA Reports of Deaths and Injuries From Use of Antimalarial hydroxychloroquine in COVID-19 Patients

April 23, 2020 — The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication today reminding doctors ...

April 24, 2020

The American College of Cardiology (ACC) released a list of the latest practice-changing presentations at the ACC.20 annual meeting March 28-30, 2020, in Chicago. This includes five late-breaking clinical trial (LBCT) sessions and three featured clinical research sessions. There also are two LBCT deep-dive sessions where the experts will break down the hottest trials and attendees can find out what the impact might be on the practice of cardiology and patients.

Feature | ACC | Dave Fornell, Editor

ACC 2020 Late-breaking Presentations

Here is the list of American College of Cardiology (ACC) practice-changing late-breaking study presentations at the ACC ...

April 09, 2020

ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM

News | Coronavirus (COVID-19)

No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients

April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether ...

April 08, 2020

$Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) #ACC20/#WCCardio$

News | Heart Failure

Vericiguat Improves Outcomes in Patients with Worsening Heart Failure

March 29, 2020 — Patients with worsening heart failure and reduced ejection fraction who received the investigational ...

March 29, 2020

POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020

News | Atrial Fibrillation

March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing ...

March 29, 2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

News | Pharmaceuticals | Dave Fornell, Editor

Two-Dose a Year LDL-lowering Drug Had Significant Impact in Pooled Analysis of ORION Trials

March 28. 2020 — Among adults with heterozygous familial hypercholesterolemia, those who received the drug inclisiran ...

March 28, 2020

News | Heart Failure

Dapagliflozin Reduces Heart Failure Worsening and Death in DAPA-HF Sub-analysis

March 28, 2020 — New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse ...

March 28, 2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

News | Antiplatelet and Anticoagulation Therapies

Antiplatelet Genetic Testing Missed Goal to Cut Cardiovascular Events in Half

March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to ...

March 28, 2020

The VOYAGER PAD trial showed patients with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg had a 15 percent reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone. #ACC20

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces Risks in Peripheral Artery Disease Post-Intervention

March 28, 2020 — People with symptomatic peripheral artery disease (PAD) who took the blood thinner rivaroxaban with ...

March 28, 2020